A $1 million seed funding is taking Humabiologics, Inc. closer to the market with its unique biomedical product. The Phoenix company, among the 2019 finalists in the BIO International Startup Stadium, is a regenerative medicine company founded by scientists and tissue industry experts.
Last year, one of those finalists was Humabiologics, a company that extracts collagen, one of the building blocks of human organs, from donated tissue and sells it to researchers. This can be used by scientists to recreate miniaturized organs or skin in the lab.
PHOENIX, Ariz.– Humabiologics Inc., a regenerative medicine company founded by scientists and tissue industry experts, announced today it has successfully raised $1 million in seed funding.
Six bioscience companies creating innovative solutions to improve regenerative medicine, spinal surgery, sleep health, medical payments, the food supply, and even ear cleaning have been selected for the 2020 Flinn Foundation Bioscience Entrepreneurship Program.
Humabiologics provides a stable supply of high–quality, human-derived biomaterials for tissue engineering, research, and regenerative medicine. The company, dedicated to bridging the gap between researchers and the gift of donated human tissues, partners with academic and industry institutions to develop biomaterials to address debilitating diseases and improve the quality of life for patients.
Eight Arizona biotech and tech startups landed funding on Feb. 20 from a Valley pitch contest and an entrepreneurship program.
Humabiologics, a Phoenix-based startup that extends the gift of donation to provide human-derived biomaterials and stem cells to empower tomorrow’s innovations.
Copyright © 2018 Humabiologics, Inc - All Rights Reserved.